Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Hm781-36
2. Hm781-36b
1. 1092364-38-9
2. Hm781-36b
3. Nov120101
4. Unii-oei6oou6ik
5. Poziotinib [inn]
6. Nov-120101
7. Hm-781-36b
8. Poziotinib [usan]
9. 1-[4-[4-(3,4-dichloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]prop-2-en-1-one
10. 1-(4-((4-((3,4-dichloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
11. Oei6oou6ik
12. Hm-781-36
13. Nov-1201
14. Mfcd28044290
15. Hm 781-36b
16. 1-[4-[[4-[(3,4-dichloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-piperidinyl]-2-propen-1-one
17. 2-propen-1-one, 1-[4-[[4-[(3,4-dichloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-piperidinyl]-
18. 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one
19. 1-[4-({4-[(3,4-dichloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)piperidin-1-yl]prop-2-en-1-one
20. 2-propen-1-one, 1-(4-((4-((3,4-dichloro-2-fluorophenyl)amino)-7-methoxy-6-quinazolinyl)oxy)-1-piperidinyl)-
21. Hm-78136b
22. Poziotinib [who-dd]
23. C23h21cl2fn4o3
24. Poziotinib (hm781-36b)
25. Gtpl7903
26. Schembl3391764
27. Chembl3545154
28. Dtxsid80148853
29. Ex-a528
30. Hms3673k03
31. Amy24248
32. Bcp08270
33. Who 9736
34. Bdbm50468247
35. Nsc783296
36. Nsc800856
37. S7358
38. Zinc95930125
39. Akos026674078
40. Ccg-264748
41. Cs-3942
42. Db12114
43. Nov 120101
44. Nsc-783296
45. Nsc-800856
46. Sb16882
47. Ncgc00386427-01
48. Ncgc00386427-02
49. Ac-29021
50. As-74851
51. Bp161454
52. Da-47945
53. Hy-15730
54. Sy235762
55. Hm 781-36
56. Ft-0752903
57. A13044
58. J-690026
59. Q27088426
60. 1-(4-((4-(3,4-dichloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl)oxy(piperidin-1-yl)prop-2-en-1-one
61. 1-[4-[4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazoline-6-yloxy]-1-piperidinyl]-2-propene-1-one
Molecular Weight | 491.3 g/mol |
---|---|
Molecular Formula | C23H21Cl2FN4O3 |
XLogP3 | 5.4 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 6 |
Exact Mass | 490.0974741 g/mol |
Monoisotopic Mass | 490.0974741 g/mol |
Topological Polar Surface Area | 76.6 Ų |
Heavy Atom Count | 33 |
Formal Charge | 0 |
Complexity | 684 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
ABOUT THIS PAGE
76
PharmaCompass offers a list of Poziotinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Poziotinib manufacturer or Poziotinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Poziotinib manufacturer or Poziotinib supplier.
PharmaCompass also assists you with knowing the Poziotinib API Price utilized in the formulation of products. Poziotinib API Price is not always fixed or binding as the Poziotinib Price is obtained through a variety of data sources. The Poziotinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Poziotinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Poziotinib, including repackagers and relabelers. The FDA regulates Poziotinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Poziotinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Poziotinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Poziotinib supplier is an individual or a company that provides Poziotinib active pharmaceutical ingredient (API) or Poziotinib finished formulations upon request. The Poziotinib suppliers may include Poziotinib API manufacturers, exporters, distributors and traders.
click here to find a list of Poziotinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Poziotinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Poziotinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Poziotinib GMP manufacturer or Poziotinib GMP API supplier for your needs.
A Poziotinib CoA (Certificate of Analysis) is a formal document that attests to Poziotinib's compliance with Poziotinib specifications and serves as a tool for batch-level quality control.
Poziotinib CoA mostly includes findings from lab analyses of a specific batch. For each Poziotinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Poziotinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Poziotinib EP), Poziotinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Poziotinib USP).